IL17A and psoriasis: Most importantly, the promising results of the phase 2 and phase 3 clinical trials studying the nanobody sonelokimab and the monoclonal antibody (mAb) bimekizumab, respectively, both of which target IL-17A, IL-17F, and IL-17A/F, further highlight the clinical relevance of IL-17F in psoriasis patients (34, 35).